Table 2 Incidence rates (IR) for the association of sex steroid treatment with all primary and secondary study outcomes
Laboratory confirmed SARS-CoV-2 infection | Outpatient visits/inpatient hospitalizations with/without ICU admission | Death due to COVID-19 | |||||
|---|---|---|---|---|---|---|---|
Exposure | Number of persons | Median follow-up (years) | IR per 1000 person-years (95% CIs) | Median follow-up (years) | IR per 1000 person-years (95% CIs) | Median follow-up (years) | IR per 1000 person-years (95% CIs) |
Local estrogens alone | 9981 | 0.99863 | 111.6 (104.9–118.6) | 0.96 | 41.3 (37.2–45.6) | 0.999 | 5.3 (3.9–7.0) |
Systemic estrogens without progestogens | 3189 | 0.99863 | 138.2 (125.4–152.1) | 0.97 | 23.5 (18.4–29.6) | 0.999 | 1.6 (0.5–3.7) |
Estrogens and progestogens | 8352 | 0.99863 | 145.2 (137.1–153.7) | 0.96 | 14.8 (12.3–17.7) | 0.999 | 0.0 (0.0–0.0) |
Progestogens alone | 9323 | 0.99863 | 150.1 (142.3–158.2) | 0.96 | 18.3 (15.6–21.2) | 0.999 | 0.2 (0.0–0.8) |
Tibolone alone | 923 | 0.99863 | 156.0 (131.6–156.0) | 0.98 | 25.2 (16.0–37.8) | 0.999 | 0.0 (0.0–0.3) |